R-Palmitoyl-(2-methyl) Ethanolam

Confirm delete?

R-Palmitoyl-(2-methyl) Ethanolamide

Zoom

Cat No: 90357

Biochemicals - Lipids

R-Palmitoyl-(2-methyl) ethanolamide (RP-2ME) is a metabolically stable analog of the anti-inflammatory endogenous cannabinoid, palmitoyl ethanolamide (PEA). PEA is an endogenous cannabinoid found in brain, liver, and other mammalian tissues.{2415} PEA...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-(2R-hydroxypropyl)-hexadecanamide

Correlated keywords:

PEA cannabinoids analogs anandamides methanandamides CB2 receptors ethanolamides inhibits inhibitors (R)-N-(2-hydroxypropyl)-hexadecanamide FAAH fatty acids hydrolases agonists neurochemistry neuroscience ethanolamines

Product Overview:
R-Palmitoyl-(2-methyl) ethanolamide (RP-2ME) is a metabolically stable analog of the anti-inflammatory endogenous cannabinoid, palmitoyl ethanolamide (PEA). PEA is an endogenous cannabinoid found in brain, liver, and other mammalian tissues.{2415} PEA has also been isolated from egg yolk, and found to have anti-anaphylactic and anti-inflammatory activity in vitro.{1633} RP-2ME is a synthetic analog of PEA which incorporates an (R)-methyl group vicinal to the alcohol on the ethanolamine moiety. RP-2ME inhibits FAAH-mediated hydrolysis of AEA by 54% at a concentration of 100 µM.{9113} It also has weak CB receptor affinity, in that 100 µM inhibits agonist binding (1 nM CP 55,940 or WIN 55,212-2) only 26% and 15.5% at the human CB1 and CB2 receptors, respectively.{9113}

Size	5 mg
Shipping	wet ice
CAS Number	179951-56-5
Molecular Formula	C₁₉H₃₉NO₂
SMILES	CCCCCCCCCCCCCCCC(=O)NC[C@@H](C)O
Molecular Weight	313,5
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2915.90
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.